PATIENTS AT HLTH IMPACT PROGRAM: Will the pace of cancer innovation lead to poorer outcomes?

In the last five years, the FDA approved more than 200 cancer drugs, and today more than half of all clinical trials are for cancer. Cancer innovation has never happened so rapidly. On its face, we are in reach of curing cancer. But are we, really? Most cancer patients are seen at community hospitals and treated by generalist oncologists, and it is estimated that a physician would need to read an impossible 29 hours a working day to stay updated about new medical research. So how do we enable rapid dissemination of innovation? To unlock this potential and avoid an acceleration of health inequities, we have to enable patients to be active, informed participants in their own healthcare; the system does not scale without them and today the system is working against them. Join us as we share the results and implications of the first-ever study measuring patient empowerment in the U.S., conducted in partnership with Outcomes4Me, the HLTH Foundation, Publicis Health, and Boston Consulting Group.